Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952504 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
A Phase 3 study of Endometrial Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,123
- Enrollment target
- 20
- Study locations
NCT06952504: Recruiting Phase 3 study of Endometrial Cancer, sponsored by Merck Sharp & Dohme.
NCT06952504 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,123 participants, above the 518-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (117% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06952504, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,123 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Primary Outcome
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as evaluated by the blinded independent central review (BICR). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesi
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- BIOLOGICAL Sacituzumab Tirumotecan
Study Locations (20)
Florida
- Florida Cancer Specialists - South ( Site 7003) - Fort Myers
- UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026) - Gainesville
- Mount Sinai Cancer Center ( Site 6031) - Miami Beach
- AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002) - Orlando
- Florida Cancer Specialists ( Site 7002) - St. Petersburg
- Florida Cancer Specialists East ( Site 7001) - West Palm Beach
California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) - Orange
- John Muir Health Cancer Center ( Site 6028) - Walnut Creek
Louisiana
- Women's Cancer Care ( Site 6010) - Covington
- TRIALS 365 ( Site 6005) - Shreveport
Alabama
- University of South Alabama, Mitchell Cancer Institute ( Site 6033) - Mobile
Alaska
- Alaska Women's Cancer Care ( Site 6036) - Anchorage
Connecticut
- Yale University School of Medicine ( Site 6009) - New Haven
District of Columbia
- MedStar Washington Hospital Center ( Site 5005) - Washington D.C.
Georgia
- St. Joseph's/Candler Health System ( Site 6021) - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,123 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2032-05-24 |
| Phase | Phase 3 |
What NCT06952504 shows while recruiting
NCT06952504 is an interventional study that assigns participants to a tested intervention. Its 1,123 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (117% higher).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06952504 names 20 study sites across 13 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06952504 about?
NCT06952504 is a clinical study titled "A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)". Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel...
What is the current status of trial NCT06952504?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,123 participants. The study started on 2025-05-22. Estimated completion is 2032-05-24.
What conditions does trial NCT06952504 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06952504?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Sacituzumab Tirumotecan (BIOLOGICAL).
Who is sponsoring clinical trial NCT06952504?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952504 being conducted?
This trial has 20 study locations across Alabama, Alaska, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06952504's enrollment target sits among peer trials
1,123 11th of 181 higher than 171 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05438329 · 1,123 participants · Phase 1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI